| Autor: |
Naser JA; Department of Cardiovascular Medicine (J.A.N., A.T., T.H., Y.N.V.R., B.A.B.), Mayo Clinic, Rochester, MN., Tada A; Department of Cardiovascular Medicine (J.A.N., A.T., T.H., Y.N.V.R., B.A.B.), Mayo Clinic, Rochester, MN., Harada T; Department of Cardiovascular Medicine (J.A.N., A.T., T.H., Y.N.V.R., B.A.B.), Mayo Clinic, Rochester, MN., Reddy YNV; Department of Cardiovascular Medicine (J.A.N., A.T., T.H., Y.N.V.R., B.A.B.), Mayo Clinic, Rochester, MN., Carter RE; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL (R.E.C.)., Testani JM; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (J.M.T.)., Jensen MD; Department of Medicine, Division of Endocrinology, Diabetes and Metabolism (M.D.J.), Mayo Clinic, Rochester, MN., Borlaug BA; Department of Cardiovascular Medicine (J.A.N., A.T., T.H., Y.N.V.R., B.A.B.), Mayo Clinic, Rochester, MN. |
| Abstrakt: |
Competing Interests: Disclosures Dr Borlaug receives research support from the National Institutes of Health (NIH) and the US Department of Defense, and research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, Rivus, and Tenax Therapeutics, as well. He has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations, and is named inventor (US Patent No. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. |
